Table 1 |
||
|
Demographics and clinical characteristics of patients used for the serum and urine biomarker validation studies |
||
|
Serum1 |
Urine1 |
|
|
|
||
|
No. |
28 |
27 |
|
Female, no. (%) |
25 (89.3) |
21 (77.8) |
|
Age, mean +/- SE, years |
37.3 ± 1.8 |
34.6 ± 2.3 |
|
Race, African American/Hispanic/Caucasian, no. |
17/8/2 |
13/12/1 |
|
SLEDAI, median (interquartile) |
10 (3 to 16) |
10 (2 to 16) |
|
Renal SLEDAI, median (interquartile) |
5 (0 to 8) |
5 (0 to 8) |
|
No. of patients with renal SLEDAI = 0 (%) |
10 (35.7) |
9 (33.3) |
|
Protein:creatinine ratio, mg/mg, mean +/- SE |
2.0 ± 0.5 |
2.3 ± 0.5 |
|
Serum Cr, mg/dl, mean +/- SE |
1.3 ± 0.2 |
1.4 ± 0.2 |
|
Comorbidities, no. (%) |
||
|
Diabetes Melitus |
3 (10.7) |
4 (14.8) |
|
Hypertension |
20 (71.4) |
20 (74.1) |
|
Dyslipidemia |
12 (42.8) |
15 (55.6) |
|
Cardiovascular disease |
4 (14.3) |
3 (11.1) |
|
Anemia |
16 (57.1) |
18 (66.7) |
|
Antiphospholipid syndrome |
3 (10.7) |
3 (11.1) |
|
Venous thromboembolism |
3 (10.7) |
3 (11.1) |
|
Others |
14 (50%) |
11 (40.7) |
|
Current medications, no. (%) |
||
|
Prednisone |
17 (60.7) |
20 (74) |
|
Mycophenolic acid |
7 (25) |
7 (25.9) |
|
Cyclophosphamide |
1 (3.6) |
2 (7.4) |
|
Azathioprine/MTX |
6 (21.4) |
3 (11.1) |
|
Cyclosporine/Tacrolimus |
2 (7.1) |
1 (3.7) |
|
Hydrochloroquine |
12 (42.9) |
11 (40.7) |
|
Angiotensin blocking agents |
14 (50) |
16 (59.3) |
|
|
||
|
1Note that 16 SLE patients had provided both serum and urine samples. |
||
|
Vanarsa et al. Arthritis Research & Therapy 2012 14:R182 doi:10.1186/ar4012 |
||
